The­seus goes back to pre­clin­i­cal mode af­ter ax­ing lead tar­get­ed ther­a­py over tol­er­a­bil­i­ty con­cerns, shares plum­met

The­seus Phar­ma­ceu­ti­cals has run in­to dose-lim­it­ing tox­i­c­i­ties that’s forc­ing the com­pa­ny to aban­don its KIT in­hibitor, two months af­ter pre­sent­ing ini­tial da­ta on the pro­gram at AS­CO.

Re­searchers are wind­ing down the on­go­ing Phase I/II study and end­ing the de­vel­op­ment of THE-630 in pa­tients with gas­troin­testi­nal stro­mal tu­mors (GIST) al­to­geth­er af­ter in­ves­ti­ga­tors flagged two cas­es of hand-foot skin re­ac­tion out of six pa­tients who got a 27 mg dose.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER